Gene therapy or recombinant protein delivery of FST has shown significant efficacy in treating muscle atrophy and muscular dystrophy, and it promotes myocyte proliferation through the activation of the PI3K/Akt/mTOR signaling pathway [98–100]. Here, AKT1 is linked to muscular dystrophy.